Clinical Trial Update: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 protocol update for DLCL002 in high-risk aggressive B-cell lymphoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Transformed Lymphoma

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Status: UNKNOWN